Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oseltamivir - Roche

Drug Profile

Oseltamivir - Roche

Alternative Names: EN 241104; GS 4104; GS 4104-002; Ke Wei; Kewei; Oseltamivir phosphate; RO 640796; RO 640796/002; Tamiflu; Tamiflu Dry Syrup

Latest Information Update: 24 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Australian National University; Gilead Sciences; University of California at Berkeley
  • Developer Chugai Pharmaceutical; HEC Pharm; Roche
  • Class Acetamides; Antivirals; Cyclohexenes; Esters; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 23 Jul 2019 Sanofi acquire the exclusive over-the-counter (OTC) rights for oseltamivir in USA
  • 28 Aug 2018 No recent reports of development identified for phase-I development in Influenza-virus-infections(In adolescents, In children, In infants, In neonates) in Belgium (PO, Capsule)
  • 28 Aug 2018 No recent reports of development identified for phase-I development in Influenza-virus-infections(In adolescents, In children, In infants, In neonates) in Belgium (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top